Expansion of the Nonclinical Safety Testing Business through the Acquisition of the 安評センター Business

「In the drug-discovery support business, we focused on obtaining orders for clinical studies and high-value-added preclinical studies, including carcinogenicity studies. Although orders received increased year on year, the number of completed studies during the cumulative first quarter of the fiscal year under review was low, resulting in a year-on-year decline in revenue.」

「At 株式会社トランスジェニック, we worked to expand high-value-added new services, including short-term carcinogenicity testing using rasH2 mice, which enables carcinogenicity to be evaluated in a shorter period than conventional long-term carcinogenicity testing, medium-term skin carcinogenicity testing, for which contract services began in 2024, and medium-term colorectal carcinogenicity testing using rats, for which we began accepting contracts.」

「The company worked to expand high-value-added new services, including short-term carcinogenicity testing using rasH2 mice, which enables carcinogenicity to be assessed in a shorter period than with conventional long-term carcinogenicity tests, intermediate-term skin carcinogenicity testing, for which outsourced testing began in 2024, and intermediate-term colorectal carcinogenicity testing using rats, for which outsourced testing also began.」

「The drug discovery support business reported orders of ¥2,133.194 million, or 105.04% of the previous fiscal year's level, and an order backlog of ¥1,615.037 million, or 117.72% of the previous fiscal year's level.」

「株式会社安評センター focused on obtaining high-value-added and differentiable tests, and orders for new services such as intermediate-term carcinogenicity testing increased.」

「As part of its chemical safety testing services, the company established and began providing an outsourced service for intermediate-term carcinogenicity testing, which predicts the carcinogenicity of chemicals with high accuracy over a short period.」

「At 安評センター, the number of outsourced testing projects increased on the back of strong orders from overseas for genotoxicity tests. However, the effect on revenue during the third quarter consolidated cumulative period was limited because many tests were still in progress.」

「Following this decision, operations at the animal testing facility, a key facility of the Central Research Institute, were suspended as planned after completion of tests for which orders had already been received. As a result, revenue at 新薬リサーチセンター declined year on year. At 安評センター, the sharing of the customer base and integrated sales activities with 新薬リサーチセンター increased the number of outsourced testing projects, but the effect on revenue during the second quarter consolidated cumulative period was limited because many tests were still in progress.」

「At 安評センター, as the business was consolidated, the sharing of the customer base and integrated sales activities with 新薬リサーチセンター increased the number of outsourced testing projects. However, the effect on revenue during the first quarter consolidated cumulative period was limited because many tests were still in progress.」

「Orders for large-animal studies, including monkeys and pigs, remained solid at subsidiary 株式会社新薬リサーチセンター. At 安評センター, orders for overseas genotoxicity studies and large-animal studies also became more active, indicating steady progress from the investments.」

「Orders for large-animal studies, including monkeys and pigs, remained solid at subsidiary 株式会社新薬リサーチセンター. At 安評センター, orders for overseas genotoxicity studies and large-animal studies also became more active, indicating steady progress from the investments.」

「Regarding outsourced nonclinical testing, 株式会社安評センター focused on obtaining new orders for nonclinical large-animal studies in addition to studies involving medium- and small-sized animals, following completion in the previous fiscal year of upgrades to the large-animal housing and management facility. This was in addition to its strength in safety testing for agrochemicals and other substances.」

「Regarding outsourced nonclinical testing, 株式会社安評センター focused on obtaining new orders for nonclinical large-animal studies in addition to studies involving medium- and small-sized animals, following completion in the previous fiscal year of upgrades to the large-animal housing and management facility. This was in addition to its strength in safety testing for agrochemicals and other substances.」

「The company advanced the sharing of the customer base and integrated sales activities with its core subsidiary, 株式会社新薬リサーチセンター. It also advanced repairs and upgrades to the large-animal housing and management facility to fully utilize its capabilities, establishing a system for obtaining new orders for nonclinical large-animal studies in addition to studies involving medium- and small-sized animals.」

「At 株式会社安評センター, the company advanced repairs and upgrades to the large-animal housing and management facility and established a system for obtaining new orders for nonclinical large-animal studies in addition to studies involving medium- and small-sized animals.」

「At 株式会社安評センター, repairs and upgrades to the large-animal housing and management facility were completed and the testing acceptance system was put in place. The company focused on obtaining new orders for nonclinical large-animal studies in addition to studies involving the medium- and small-sized animals used previously.」

「At 株式会社安評センター, repairs and upgrades to the large-animal housing and management facility were completed, and a permit to house and manage primates was obtained in March 2019 through applications to the relevant government ministries and agencies. This enabled the company to provide nonclinical large-animal testing services, from pharmacological efficacy studies through safety testing, using primates in addition to dogs.」

「In addition, 株式会社安評センター, a consolidated subsidiary, acquired the business from 公益財団法人食品農医薬品安全性評価センター on 1 April last year. As a result, the CRO business's order backlog at the end of the third quarter consolidated accounting period increased substantially to ¥984.349 million, up 63.0% year on year, while its capacity to accept nonclinical safety tests across a broad range of fields also expanded significantly.」

「In addition, on 1 April of this year, consolidated subsidiary 株式会社安評センター acquired the business of 公益財団法人食品農医薬品安全性評価センター. As a result, the CRO business's order backlog at the end of the second quarter increased sharply to ¥1,127.929 million, up 163.4% year on year, while its capacity to accept nonclinical safety testing projects across a broad range of fields also expanded substantially.」

「On 1 April of the current year, the Company's consolidated subsidiary 株式会社安評センター acquired the business of 公益財団法人食品農医薬品安全性評価センター. As a result, CRO business order backlog at the end of the first quarter of the current consolidated fiscal year increased substantially to ¥1,209 million, up 182.4% year on year, and its capacity to accept orders for nonclinical safety studies across a broad range of fields also expanded significantly.」